What is Cinobac used for?

Cinobac is indicated for Urinary tract infectious disease.

Cinobac is developed by Eli Lilly.

What development phase is Cinobac in?

Cinobac is FDA-approved (marketed).

What is the generic name of Cinobac?

CINOXACIN is the generic (nonproprietary) name of Cinobac.

Last reviewed 2026-04-20 · How we verify

Cinobac (CINOXACIN)

Eli Lilly · FDA-approved approved Small molecule Quality 20/100

Cinobac (Cinoxacin) is a small molecule drug developed by Lilly, targeting carbonic anhydrase 2. It is a cinoxacin class medication, approved by the FDA in 1980 for the treatment of urinary tract infectious diseases. As an off-patent medication, it is available as a generic. Key safety considerations include its bioavailability of 72%. Cinobac is currently owned by Lilly, with a single generic manufacturer.

At a glance

Generic name	CINOXACIN
Sponsor	Eli Lilly
Drug class	cinoxacin
Target	Carbonic anhydrase 2
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	FDA-approved
First approval	1980

Approved indications

Urinary tract infectious disease

Common side effects

No common side effects on file.

Drug interactions

zinc acetate

Key clinical trials

Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results